Compare Stocks → The #1 Opportunity of the decade? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACHLNASDAQ:ADVMNYSEAMERICAN:ARMPNASDAQ:EIGRNASDAQ:INMB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$0.78-2.1%$1.13$0.74▼$1.76$31.22M1.09687,430 shs200,792 shsADVMAdverum Biotechnologies$11.34+1.7%$16.57$7.10▼$29.70$235.31M0.84239,686 shs138,898 shsARMPArmata Pharmaceuticals$2.67+4.7%$0.00$1.07▼$5.26$96.52M0.8517,560 shs9,559 shsEIGREiger BioPharmaceuticals$5.04$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsINMBINmune Bio$8.37-4.9%$11.68$6.50▼$14.74$152.33M1.9987,602 shs69,216 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics-2.91%-5.88%-32.77%-2.76%-11.01%ADVMAdverum Biotechnologies-1.76%-6.85%-32.42%+31.47%+21.20%ARMPArmata Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EIGREiger BioPharmaceuticals0.00%0.00%-64.14%-74.41%-94.80%INMBINmune Bio+4.39%-19.56%-19.56%-22.40%+5.90%Will this $2 AI stock double overnight? (Ad)It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHLAchilles Therapeutics1.8858 of 5 stars3.03.00.00.02.50.81.3ADVMAdverum Biotechnologies4.0309 of 5 stars3.52.00.04.83.32.50.0ARMPArmata Pharmaceuticals2.0903 of 5 stars3.53.00.00.01.91.70.6EIGREiger BioPharmaceuticals3.8258 of 5 stars3.55.00.04.20.61.70.0INMBINmune Bio0.8139 of 5 stars3.50.00.00.01.91.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics2.00Hold$4.00410.92% UpsideADVMAdverum Biotechnologies3.00Buy$34.67205.70% UpsideARMPArmata Pharmaceuticals3.00Buy$7.00162.17% UpsideEIGREiger BioPharmaceuticals3.00Buy$120.00∞ UpsideINMBINmune Bio3.00Buy$16.0091.16% UpsideCurrent Analyst RatingsLatest ADVM, EIGR, ACHL, INMB, and ARMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024ACHLAchilles TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $6.004/5/2024ACHLAchilles TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$8.00 ➝ $2.003/22/2024ARMPArmata PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.003/19/2024ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/6/2024ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $40.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AADVMAdverum Biotechnologies$3.60M65.36N/AN/A$8.26 per share1.37ARMPArmata Pharmaceuticals$4.53M21.31N/AN/A($0.89) per share-3.00EIGREiger BioPharmaceuticals$15.77M0.00N/AN/A$37.68 per share0.00INMBINmune Bio$160K952.09N/AN/A$2.07 per share4.04Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.74N/AN/AN/AN/A-42.55%-37.54%5/8/2024 (Estimated)ADVMAdverum Biotechnologies-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%5/9/2024 (Estimated)ARMPArmata Pharmaceuticals-$69.04M-$1.98N/AN/AN/A-1,524.51%-280.95%-52.61%5/9/2024 (Estimated)EIGREiger BioPharmaceuticals-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%5/9/2024 (Estimated)INMBINmune Bio-$30.01M-$1.67N/A∞N/A-19,360.00%-64.11%-45.57%5/1/2024 (Estimated)Latest ADVM, EIGR, ACHL, INMB, and ARMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023ARMPArmata PharmaceuticalsN/A-$0.55-$0.55-$0.55$0.68 million$1.53 million3/18/2024Q4 2023ADVMAdverum Biotechnologies-$2.80-$2.30+$0.50-$2.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AARMPArmata PharmaceuticalsN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A8.578.57ADVMAdverum BiotechnologiesN/A4.134.13ARMPArmata PharmaceuticalsN/A1.161.16EIGREiger BioPharmaceuticalsN/A3.313.24INMBINmune BioN/A2.162.16OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%ADVMAdverum Biotechnologies48.17%ARMPArmata Pharmaceuticals3.57%EIGREiger BioPharmaceuticals62.46%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%ADVMAdverum Biotechnologies5.30%ARMPArmata Pharmaceuticals85.50%EIGREiger BioPharmaceuticals4.22%INMBINmune Bio36.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics20439.88 million37.73 millionNot OptionableADVMAdverum Biotechnologies12120.75 million19.66 millionOptionableARMPArmata Pharmaceuticals6636.15 million5.24 millionNot OptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableINMBINmune Bio1018.20 million11.52 millionOptionableADVM, EIGR, ACHL, INMB, and ARMP HeadlinesSourceHeadlineINmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interestamericanbankingnews.com - April 16 at 5:34 AMINmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024finance.yahoo.com - April 8 at 8:33 AMINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024globenewswire.com - April 8 at 8:00 AMAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)markets.businessinsider.com - April 2 at 11:32 PMINmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 1 at 12:16 PMINmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - March 31 at 10:18 AMINmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 30 at 2:42 PMINmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancementsfinance.yahoo.com - March 29 at 7:30 PMINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Updatefinanznachrichten.de - March 29 at 9:29 AMINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Updateglobenewswire.com - March 28 at 4:01 PMINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28globenewswire.com - March 26 at 4:01 PMINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapyglobenewswire.com - March 13 at 8:00 AMINmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XProfinanznachrichten.de - March 6 at 7:23 PMBuy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developmentsmarkets.businessinsider.com - March 6 at 7:23 PMINmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™globenewswire.com - March 5 at 8:00 AMINMB Jun 2024 25.000 callfinance.yahoo.com - February 17 at 10:36 PMINMB Mar 2024 20.000 callfinance.yahoo.com - February 16 at 9:33 PMINMB Mar 2024 12.500 putfinance.yahoo.com - February 16 at 9:33 PMINMB Feb 2024 15.000 putfinance.yahoo.com - February 15 at 12:38 AMINmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 12 at 9:42 AMINmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024finance.yahoo.com - February 7 at 12:22 PMInsiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the companyfinance.yahoo.com - February 4 at 10:24 AMBuy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic Approachmarkets.businessinsider.com - February 1 at 8:23 AMInmune Bio Resumes Alzheimer’s Trial, Aims for Mid-2024 Enrollmentmsn.com - February 1 at 1:18 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAchilles TherapeuticsNASDAQ:ACHLAchilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Adverum BiotechnologiesNASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Armata PharmaceuticalsNYSEAMERICAN:ARMPArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Eiger BioPharmaceuticalsNASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.